Shopping Cart 0
Cart Subtotal
USD 0

Athersys Inc (ATHX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Athersys Inc (Athersys) is a biotechnology company that discovers and develops of novel and proprietary best-in-class therapies in the field of regenerative medicine. Its lead platform, MultiStem, is a patented stem cell product, developed for treating multiple disease indications such as cardiovascular diseases, inflammatory and immune disorders, neurological conditions and others. Its MultiStem program includes product candidates at various levels of clinical trials for treating acute myocardial infarction, bone marrow/hematopoietic stem cell transplantation, ischemic stroke and autoimmune disease. Its other program, 5HT2c agonist is used for treating obesity and other conditions such as schizophrenia. Athersys is headquartered in Cleveland, Ohio, the US.

Athersys Inc (ATHX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Athersys Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Athersys Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Athersys Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Athersys Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Athersys Inc, Medical Devices Deals, 2012 to YTD 2018 10

Athersys Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Athersys Inc, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

Athersys Enters into Partnership with MedCision 12

Athersys Enters into Co-Development Agreement for MultiStem 13

Cell Therapy Catapult Enters into Agreement with Athersys 14

Licensing Agreements 15

Athersys Expands Licensing Agreement with Healios 15

Equity Offering 17

Athersys Plans to Raise up to USD43.9 Million in Public Offering of Shares 17

Athersys Raises USD1.9 Million in Private Placement of Shares, upon Exercise of Warrants 18

Athersys Raises USD23 Million in Public Offering of Shares 19

Athersys Files Registration Statement For Public Offering Of Shares 20

Athersys Completes Private Placement Of Common Stock And Warrants For USD 20.5 Million 21

Athersys Completes Private Placement Of Common Stock And Warrants For USD 20 Million 22

Athersys Raises USD18.4 Million in Private Placement Of Shares 23

Athersys Completes Public Offering Of Common Stock For USD 23 Million 24

Athersys Completes Private Placement Of Shares For USD 9 Million 25

Athersys Inc-Key Competitors 26

Athersys Inc-Key Employees 27

Athersys Inc-Locations And Subsidiaries 28

Head Office 28

Other Locations & Subsidiaries 28

Recent Developments 29

Financial Announcements 29

Aug 07, 2018: Athersys reports second quarter 2018 results 29

May 10, 2018: Athersys Reports First Quarter 2018 Results 31

Mar 13, 2018: Athersys Reports Financial Results for Fourth Quarter, Full Year 2017 33

Nov 08, 2017: Athersys Reports Third Quarter 2017 Results 35

Aug 09, 2017: Athersys Reports Second Quarter 2017 Results 37

May 09, 2017: Athersys Reports First Quarter 2017 Results 38

Mar 09, 2017: Athersys Reports Financial Results for Fourth Quarter, Full Year 2016 39

Product News 41

02/23/2017: Overview of MultiStem Clinical Trial in Japan Presentation at International Stroke Conference 2017 41

Clinical Trials 42

Nov 15, 2017: HEALIOS Announces Enrollment of First Patient in Japan in TREASURE Study of MultiStem Treatment for Ischemic Stroke 42

Oct 25, 2017: The Status of a Clinical Trial of Adult Stem Cell Regenerative Medicine HLCM051 in Patients with Ischemic Stroke in Japan (TREASURE study) 44

Oct 05, 2017: Athersys to Present at 2017 Cell & Gene Meeting on the Mesa and Announces Regenerative Medicine Advanced Therapy Designation From FDA 45

Sep 01, 2017: The Status of a Clinical Trial of Adult Stem Cell Regenerative Medicine HLCM051 in Patients with Ischemic Stroke in Japan (TREASURE study) 46

Aug 07, 2017: Athersys Reports Alignment of Key Regulators for Pivotal Registration Study in Stroke 47

Mar 23, 2017: The Results from Athersys Phase 2 Trial of MultiStem Cell Therapy for Treating Ischemic Stroke Patients in the United States and Europe Published in Lancet Neurology 48

Mar 20, 2017: Two New Publications Highlight the Potential for MultiStem Treatment of Ischemic Stroke 49

Appendix 51

Methodology 51

About GlobalData 51

Contact Us 51

Disclaimer 51


List Of Figure

List of Figures

Athersys Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Athersys Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Athersys Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Athersys Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Athersys Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Athersys Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Athersys Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Athersys Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Athersys Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Athersys Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Athersys Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Athersys Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Athersys Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Athersys Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Athersys Inc, Medical Devices Deals, 2012 to YTD 2018 10

Athersys Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Athersys Enters into Partnership with MedCision 12

Athersys Enters into Co-Development Agreement for MultiStem 13

Cell Therapy Catapult Enters into Agreement with Athersys 14

Athersys Expands Licensing Agreement with Healios 15

Athersys Plans to Raise up to USD43.9 Million in Public Offering of Shares 17

Athersys Raises USD1.9 Million in Private Placement of Shares, upon Exercise of Warrants 18

Athersys Raises USD23 Million in Public Offering of Shares 19

Athersys Files Registration Statement For Public Offering Of Shares 20

Athersys Completes Private Placement Of Common Stock And Warrants For USD 20.5 Million 21

Athersys Completes Private Placement Of Common Stock And Warrants For USD 20 Million 22

Athersys Raises USD18.4 Million in Private Placement Of Shares 23

Athersys Completes Public Offering Of Common Stock For USD 23 Million 24

Athersys Completes Private Placement Of Shares For USD 9 Million 25

Athersys Inc, Key Competitors 26

Athersys Inc, Key Employees 27

Athersys Inc, Subsidiaries 28

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Athersys Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Athersys Inc (Athersys) is a biotechnology company that discovers and develops of novel and proprietary best-in-class therapies in the field of regenerative medicine. Its lead platform, MultiStem, is a patented stem cell product, developed for treating multiple disease indications such as cardiovascular diseases, inflammatory and immune disorders, neurological conditions and others. Its MultiStem program includes product candidates at various levels of clinical trials for treating acute myocardial infarction, bone marrow/hematopoietic stem cell transplantation, ischemic stroke and autoimmune disease. Its other program, 5HT2c agonist is used for treating obesity and other conditions such as schizophrenia. Athersys is headquartered in Cleveland, Ohio, the US.

Athersys Inc (ATHX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Athersys Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Athersys Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Athersys Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Athersys Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Athersys Inc, Medical Devices Deals, 2012 to YTD 2018 10

Athersys Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Athersys Inc, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

Athersys Enters into Partnership with MedCision 12

Athersys Enters into Co-Development Agreement for MultiStem 13

Cell Therapy Catapult Enters into Agreement with Athersys 14

Licensing Agreements 15

Athersys Expands Licensing Agreement with Healios 15

Equity Offering 17

Athersys Plans to Raise up to USD43.9 Million in Public Offering of Shares 17

Athersys Raises USD1.9 Million in Private Placement of Shares, upon Exercise of Warrants 18

Athersys Raises USD23 Million in Public Offering of Shares 19

Athersys Files Registration Statement For Public Offering Of Shares 20

Athersys Completes Private Placement Of Common Stock And Warrants For USD 20.5 Million 21

Athersys Completes Private Placement Of Common Stock And Warrants For USD 20 Million 22

Athersys Raises USD18.4 Million in Private Placement Of Shares 23

Athersys Completes Public Offering Of Common Stock For USD 23 Million 24

Athersys Completes Private Placement Of Shares For USD 9 Million 25

Athersys Inc-Key Competitors 26

Athersys Inc-Key Employees 27

Athersys Inc-Locations And Subsidiaries 28

Head Office 28

Other Locations & Subsidiaries 28

Recent Developments 29

Financial Announcements 29

Aug 07, 2018: Athersys reports second quarter 2018 results 29

May 10, 2018: Athersys Reports First Quarter 2018 Results 31

Mar 13, 2018: Athersys Reports Financial Results for Fourth Quarter, Full Year 2017 33

Nov 08, 2017: Athersys Reports Third Quarter 2017 Results 35

Aug 09, 2017: Athersys Reports Second Quarter 2017 Results 37

May 09, 2017: Athersys Reports First Quarter 2017 Results 38

Mar 09, 2017: Athersys Reports Financial Results for Fourth Quarter, Full Year 2016 39

Product News 41

02/23/2017: Overview of MultiStem Clinical Trial in Japan Presentation at International Stroke Conference 2017 41

Clinical Trials 42

Nov 15, 2017: HEALIOS Announces Enrollment of First Patient in Japan in TREASURE Study of MultiStem Treatment for Ischemic Stroke 42

Oct 25, 2017: The Status of a Clinical Trial of Adult Stem Cell Regenerative Medicine HLCM051 in Patients with Ischemic Stroke in Japan (TREASURE study) 44

Oct 05, 2017: Athersys to Present at 2017 Cell & Gene Meeting on the Mesa and Announces Regenerative Medicine Advanced Therapy Designation From FDA 45

Sep 01, 2017: The Status of a Clinical Trial of Adult Stem Cell Regenerative Medicine HLCM051 in Patients with Ischemic Stroke in Japan (TREASURE study) 46

Aug 07, 2017: Athersys Reports Alignment of Key Regulators for Pivotal Registration Study in Stroke 47

Mar 23, 2017: The Results from Athersys Phase 2 Trial of MultiStem Cell Therapy for Treating Ischemic Stroke Patients in the United States and Europe Published in Lancet Neurology 48

Mar 20, 2017: Two New Publications Highlight the Potential for MultiStem Treatment of Ischemic Stroke 49

Appendix 51

Methodology 51

About GlobalData 51

Contact Us 51

Disclaimer 51


List Of Figure

List of Figures

Athersys Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Athersys Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Athersys Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Athersys Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Athersys Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Athersys Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Athersys Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Athersys Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Athersys Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Athersys Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Athersys Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Athersys Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Athersys Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Athersys Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Athersys Inc, Medical Devices Deals, 2012 to YTD 2018 10

Athersys Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Athersys Enters into Partnership with MedCision 12

Athersys Enters into Co-Development Agreement for MultiStem 13

Cell Therapy Catapult Enters into Agreement with Athersys 14

Athersys Expands Licensing Agreement with Healios 15

Athersys Plans to Raise up to USD43.9 Million in Public Offering of Shares 17

Athersys Raises USD1.9 Million in Private Placement of Shares, upon Exercise of Warrants 18

Athersys Raises USD23 Million in Public Offering of Shares 19

Athersys Files Registration Statement For Public Offering Of Shares 20

Athersys Completes Private Placement Of Common Stock And Warrants For USD 20.5 Million 21

Athersys Completes Private Placement Of Common Stock And Warrants For USD 20 Million 22

Athersys Raises USD18.4 Million in Private Placement Of Shares 23

Athersys Completes Public Offering Of Common Stock For USD 23 Million 24

Athersys Completes Private Placement Of Shares For USD 9 Million 25

Athersys Inc, Key Competitors 26

Athersys Inc, Key Employees 27

Athersys Inc, Subsidiaries 28

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Athersys Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.